CA3066446A1 - Anti-obesity potential of garcinol - Google Patents
Anti-obesity potential of garcinol Download PDFInfo
- Publication number
- CA3066446A1 CA3066446A1 CA3066446A CA3066446A CA3066446A1 CA 3066446 A1 CA3066446 A1 CA 3066446A1 CA 3066446 A CA3066446 A CA 3066446A CA 3066446 A CA3066446 A CA 3066446A CA 3066446 A1 CA3066446 A1 CA 3066446A1
- Authority
- CA
- Canada
- Prior art keywords
- garcinol
- fat
- mammals
- obesity
- hfd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DTTONLKLWRTCAB-UDFURZHRSA-N (1s,3e,5r,7r)-3-[(3,4-dihydroxyphenyl)-hydroxymethylidene]-6,6-dimethyl-5,7-bis(3-methylbut-2-enyl)-1-[(2s)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]bicyclo[3.3.1]nonane-2,4,9-trione Chemical compound O=C([C@@]1(C(C)(C)[C@H](CC=C(C)C)C[C@](C2=O)(C1=O)C[C@H](CC=C(C)C)C(C)=C)CC=C(C)C)\C2=C(\O)C1=CC=C(O)C(O)=C1 DTTONLKLWRTCAB-UDFURZHRSA-N 0.000 title claims abstract description 148
- QDKLRKZQSOQWJQ-JGWHSXGBSA-N Garcinol Natural products O=C([C@@]1(C(C)(C)[C@@H](CC=C(C)C)C[C@](C=2O)(C1=O)C[C@H](CC=C(C)C)C(C)=C)CC=C(C)C)C=2C(=O)C1=CC=C(O)C(O)=C1 QDKLRKZQSOQWJQ-JGWHSXGBSA-N 0.000 title claims abstract description 147
- LMFLOMBYUXRHIL-UHFFFAOYSA-N garcifuran-A Natural products COC1=C(O)C(OC)=CC(C=2C(=C3C=COC3=CC=2)O)=C1 LMFLOMBYUXRHIL-UHFFFAOYSA-N 0.000 title claims abstract description 147
- GRBCIRZXESZBGJ-UHFFFAOYSA-N guttiferone F Natural products CC(=CCCC(C(=C)C)C12CC(CC=C(C)C)C(C)(C)C(CC=C(C)C)(C(=O)C(=C1O)C(=O)c3ccc(O)c(O)c3)C2=O)C GRBCIRZXESZBGJ-UHFFFAOYSA-N 0.000 title claims abstract description 147
- 230000003579 anti-obesity Effects 0.000 title description 15
- 239000000203 mixture Substances 0.000 claims abstract description 43
- 208000008589 Obesity Diseases 0.000 claims abstract description 32
- 244000005709 gut microbiome Species 0.000 claims abstract description 31
- 235000020824 obesity Nutrition 0.000 claims abstract description 31
- 241000124008 Mammalia Species 0.000 claims abstract description 23
- 241000702462 Akkermansia muciniphila Species 0.000 claims abstract description 11
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 8
- 230000004048 modification Effects 0.000 claims abstract description 5
- 238000012986 modification Methods 0.000 claims abstract description 5
- 230000001413 cellular effect Effects 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 36
- 108090000623 proteins and genes Proteins 0.000 claims description 36
- 230000001965 increasing effect Effects 0.000 claims description 32
- 210000001789 adipocyte Anatomy 0.000 claims description 29
- 230000000694 effects Effects 0.000 claims description 29
- 230000014509 gene expression Effects 0.000 claims description 24
- 230000011759 adipose tissue development Effects 0.000 claims description 23
- 230000037396 body weight Effects 0.000 claims description 20
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 19
- 108010010234 HDL Lipoproteins Proteins 0.000 claims description 16
- 102000015779 HDL Lipoproteins Human genes 0.000 claims description 16
- 108010007622 LDL Lipoproteins Proteins 0.000 claims description 16
- 102000007330 LDL Lipoproteins Human genes 0.000 claims description 16
- 230000005764 inhibitory process Effects 0.000 claims description 15
- 210000002966 serum Anatomy 0.000 claims description 13
- 230000008859 change Effects 0.000 claims description 12
- 210000001596 intra-abdominal fat Anatomy 0.000 claims description 10
- 108010062497 VLDL Lipoproteins Proteins 0.000 claims description 8
- 150000003626 triacylglycerols Chemical class 0.000 claims description 8
- 101710119301 Protein delta homolog 1 Proteins 0.000 claims description 7
- 241001202853 Blautia Species 0.000 claims description 6
- 102100036467 Protein delta homolog 1 Human genes 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 239000000969 carrier Substances 0.000 claims description 6
- 235000009508 confectionery Nutrition 0.000 claims description 6
- 230000007423 decrease Effects 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 6
- -1 gummies Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 210000000229 preadipocyte Anatomy 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 235000020357 syrup Nutrition 0.000 claims description 6
- 239000006188 syrup Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 241000606125 Bacteroides Species 0.000 claims description 5
- 241000337504 Bacteroides stercorirosoris Species 0.000 claims description 5
- 241000115153 Bacteroides xylanisolvens Species 0.000 claims description 5
- 241000186560 Blautia coccoides Species 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 235000013406 prebiotics Nutrition 0.000 claims description 5
- 241000144235 Anaerobranca Species 0.000 claims description 4
- 102100024594 Histone-lysine N-methyltransferase PRDM16 Human genes 0.000 claims description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 150000001200 N-acyl ethanolamides Chemical class 0.000 claims description 4
- 241000266824 Oscillospira Species 0.000 claims description 4
- 239000002621 endocannabinoid Substances 0.000 claims description 4
- 230000003827 upregulation Effects 0.000 claims description 4
- 241000605059 Bacteroidetes Species 0.000 claims description 3
- 241000192125 Firmicutes Species 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 241000186660 Lactobacillus Species 0.000 claims description 3
- 102000016267 Leptin Human genes 0.000 claims description 3
- 108010092277 Leptin Proteins 0.000 claims description 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 3
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 3
- 102000007156 Resistin Human genes 0.000 claims description 3
- 108010047909 Resistin Proteins 0.000 claims description 3
- 241001261005 Verrucomicrobia Species 0.000 claims description 3
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
- 210000001593 brown adipocyte Anatomy 0.000 claims description 3
- 229940039696 lactobacillus Drugs 0.000 claims description 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 3
- 229940039781 leptin Drugs 0.000 claims description 3
- 230000019491 signal transduction Effects 0.000 claims description 3
- 241000428313 Anaerotruncus colihominis Species 0.000 claims description 2
- 241000217846 Bacteroides caccae Species 0.000 claims description 2
- 241001038648 Blautia wexlerae Species 0.000 claims description 2
- 241000605902 Butyrivibrio Species 0.000 claims description 2
- 241000193403 Clostridium Species 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 241001240316 Emticicia Species 0.000 claims description 2
- 241000159554 Johnsonella ignava Species 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 241001660097 Pedobacter Species 0.000 claims description 2
- 241000192142 Proteobacteria Species 0.000 claims description 2
- 241001604192 [Clostridium] alkalicellulosi Species 0.000 claims description 2
- 241001147719 [Clostridium] termitidis Species 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 230000003828 downregulation Effects 0.000 claims description 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 claims 2
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 claims 2
- 230000003248 secreting effect Effects 0.000 claims 2
- 241001145875 Actinomyces naturae Species 0.000 claims 1
- 102100022089 Acyl-[acyl-carrier-protein] hydrolase Human genes 0.000 claims 1
- 241001101538 Alkaliphilus crotonatoxidans Species 0.000 claims 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims 1
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 claims 1
- 241001143296 Deferribacteres <phylum> Species 0.000 claims 1
- 241001276248 Dolichospermum curvum Species 0.000 claims 1
- 241000024397 Dysgonomonas Species 0.000 claims 1
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 claims 1
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 claims 1
- 101000686942 Homo sapiens Histone-lysine N-methyltransferase PRDM16 Proteins 0.000 claims 1
- 101000837829 Homo sapiens Transcription factor IIIA Proteins 0.000 claims 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims 1
- 241000159562 Johnsonella Species 0.000 claims 1
- 241000186869 Lactobacillus salivarius Species 0.000 claims 1
- 102100029820 Mitochondrial brown fat uncoupling protein 1 Human genes 0.000 claims 1
- 108050002686 Mitochondrial brown fat uncoupling protein 1 Proteins 0.000 claims 1
- 101100439101 Mus musculus Cebpa gene Proteins 0.000 claims 1
- 102000017946 PGC-1 Human genes 0.000 claims 1
- 108700038399 PGC-1 Proteins 0.000 claims 1
- 241000030714 Parabacteroides goldsteinii Species 0.000 claims 1
- 241001607074 Peptoniphilus coxii Species 0.000 claims 1
- 241000156172 Rhodothermus clarus Species 0.000 claims 1
- 241000192031 Ruminococcus Species 0.000 claims 1
- 101001062859 Sus scrofa Fatty acid-binding protein, adipocyte Proteins 0.000 claims 1
- 102100028509 Transcription factor IIIA Human genes 0.000 claims 1
- 241001464867 [Ruminococcus] gnavus Species 0.000 claims 1
- 230000002438 mitochondrial effect Effects 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 abstract description 8
- 235000019786 weight gain Nutrition 0.000 abstract description 8
- 230000004584 weight gain Effects 0.000 abstract description 6
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract description 3
- 235000009200 high fat diet Nutrition 0.000 description 75
- 241001465754 Metazoa Species 0.000 description 42
- 241000699670 Mus sp. Species 0.000 description 42
- 235000019197 fats Nutrition 0.000 description 30
- 210000000577 adipose tissue Anatomy 0.000 description 27
- 238000011282 treatment Methods 0.000 description 17
- 210000003486 adipose tissue brown Anatomy 0.000 description 15
- 210000001035 gastrointestinal tract Anatomy 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 12
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 235000005911 diet Nutrition 0.000 description 11
- 230000037213 diet Effects 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 230000004580 weight loss Effects 0.000 description 10
- 208000016261 weight loss Diseases 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 231100000673 dose–response relationship Toxicity 0.000 description 9
- 230000000813 microbial effect Effects 0.000 description 9
- 241000702460 Akkermansia Species 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 description 6
- 210000000593 adipose tissue white Anatomy 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108020004465 16S ribosomal RNA Proteins 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 229930002877 anthocyanin Natural products 0.000 description 5
- 235000010208 anthocyanin Nutrition 0.000 description 5
- 239000004410 anthocyanin Substances 0.000 description 5
- 150000004636 anthocyanins Chemical class 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 235000021590 normal diet Nutrition 0.000 description 5
- 238000001543 one-way ANOVA Methods 0.000 description 5
- 238000000513 principal component analysis Methods 0.000 description 5
- 239000006041 probiotic Substances 0.000 description 5
- 235000018291 probiotics Nutrition 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 230000035508 accumulation Effects 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 229940089491 hydroxycitric acid Drugs 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000000529 probiotic effect Effects 0.000 description 4
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 description 4
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000087349 Anaerobranca zavarzinii Species 0.000 description 3
- 241000168061 Butyrivibrio proteoclasticus Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101710122674 Histone-lysine N-methyltransferase PRDM16 Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 3
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 3
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 3
- 102100026839 Sterol regulatory element-binding protein 1 Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003466 anti-cipated effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000037149 energy metabolism Effects 0.000 description 3
- 238000013401 experimental design Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000006372 lipid accumulation Effects 0.000 description 3
- 230000004130 lipolysis Effects 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- DGAKHGXRMXWHBX-ONEGZZNKSA-N Azoxymethane Chemical compound C\N=[N+](/C)[O-] DGAKHGXRMXWHBX-ONEGZZNKSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000027244 Dysbiosis Diseases 0.000 description 2
- 208000037487 Endotoxemia Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 108010016731 PPAR gamma Proteins 0.000 description 2
- 241000160321 Parabacteroides Species 0.000 description 2
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 229920003045 dextran sodium sulfate Polymers 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000007140 dysbiosis Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000004136 fatty acid synthesis Effects 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 238000013116 obese mouse model Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 241000186046 Actinomyces Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 241000237519 Bivalvia Species 0.000 description 1
- 240000007551 Boswellia serrata Species 0.000 description 1
- 235000012035 Boswellia serrata Nutrition 0.000 description 1
- 101710168309 CCAAT/enhancer-binding protein alpha Proteins 0.000 description 1
- 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 101150061453 Cebpa gene Proteins 0.000 description 1
- 241001256780 Dolichospermum Species 0.000 description 1
- 241000827171 Dysgonomonas wimpennyi Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 241000593508 Garcinia Species 0.000 description 1
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 1
- 102100030875 Gastricsin Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 101150021539 MT-CO2 gene Proteins 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 241001050508 Mucispirillum schaedleri Species 0.000 description 1
- 229910020700 Na3VO4 Inorganic materials 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000566145 Otus Species 0.000 description 1
- 240000002834 Paulownia tomentosa Species 0.000 description 1
- 235000010678 Paulownia tomentosa Nutrition 0.000 description 1
- 108090000310 Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha Proteins 0.000 description 1
- 102100028960 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Human genes 0.000 description 1
- IIXHQGSINFQLRR-UHFFFAOYSA-N Piceatannol Natural products Oc1ccc(C=Cc2c(O)c(O)c3CCCCc3c2O)cc1O IIXHQGSINFQLRR-UHFFFAOYSA-N 0.000 description 1
- 101710191567 Probable endopolygalacturonase C Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 241001148569 Rhodothermus Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- AEOBEOJCBAYXBA-KQYNXXCUSA-N [(2r,3r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1OP(O)(O)=O AEOBEOJCBAYXBA-KQYNXXCUSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002293 adipogenic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical group CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000006583 body weight regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000020639 clam Nutrition 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000004320 controlled atmosphere Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002705 metabolomic analysis Methods 0.000 description 1
- 230000001431 metabolomic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- CDRPUGZCRXZLFL-OWOJBTEDSA-N piceatannol Chemical compound OC1=CC(O)=CC(\C=C\C=2C=C(O)C(O)=CC=2)=C1 CDRPUGZCRXZLFL-OWOJBTEDSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 231100000272 reduced body weight Toxicity 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000037221 weight management Effects 0.000 description 1
- 210000000636 white adipocyte Anatomy 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Confectionery (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762519949P | 2017-06-15 | 2017-06-15 | |
| US62/519,949 | 2017-06-15 | ||
| US201762523611P | 2017-06-22 | 2017-06-22 | |
| US62/523,611 | 2017-06-22 | ||
| PCT/US2018/037242 WO2018231923A1 (en) | 2017-06-15 | 2018-06-13 | Anti-obesity potential of garcinol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3066446A1 true CA3066446A1 (en) | 2018-12-20 |
Family
ID=64659462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3066446A Pending CA3066446A1 (en) | 2017-06-15 | 2018-06-13 | Anti-obesity potential of garcinol |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP3638226A4 (de) |
| JP (3) | JP2020523373A (de) |
| KR (1) | KR102289324B1 (de) |
| AU (1) | AU2018284354A1 (de) |
| BR (1) | BR112019026824A2 (de) |
| CA (1) | CA3066446A1 (de) |
| MX (1) | MX2019014841A (de) |
| WO (1) | WO2018231923A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102136335B1 (ko) * | 2020-03-24 | 2020-07-22 | (주)메디톡스 | 간기능 개선 또는 지방축적 억제 미생물 및 그의 용도 |
| KR102363092B1 (ko) * | 2020-06-19 | 2022-02-16 | 한국식품연구원 | 장내 미생물을 이용한 비만 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 비만 예방 또는 치료제 스크리닝 방법 |
| KR102191487B1 (ko) * | 2020-06-19 | 2020-12-15 | (주)메디톡스 | 간기능 개선 또는 지방축적 억제 미생물 및 그의 용도 |
| KR102363088B1 (ko) * | 2020-06-19 | 2022-02-16 | 한국식품연구원 | 장내 미생물을 이용한 당뇨병 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 당뇨병 예방 또는 치료제 스크리닝 방법 |
| KR102363098B1 (ko) * | 2020-06-19 | 2022-02-16 | 한국식품연구원 | 장내 미생물을 이용한 신질환 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 신질환 예방 또는 치료제 스크리닝 방법 |
| KR102363094B1 (ko) * | 2020-06-19 | 2022-02-16 | 한국식품연구원 | 장내 미생물을 이용한 간질환 위험도 예측 또는 진단용 조성물, 그를 이용한 진단키트, 정보제공방법 및 간질환 예방 또는 치료제 스크리닝 방법 |
| KR102331485B1 (ko) | 2021-08-02 | 2021-12-01 | 주식회사 바이오뱅크힐링 | 블라우티아 웩슬러래 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| CN114605242A (zh) * | 2022-04-11 | 2022-06-10 | 澳门大学 | 间苯三酚类化合物的制备方法与药物、保健产品和食品 |
| CN114847475B (zh) * | 2022-07-05 | 2022-11-29 | 广东金骏康生物技术有限公司 | 一种促进akk菌生长的发酵槐米粉的应用 |
| CN115637242A (zh) * | 2022-10-20 | 2023-01-24 | 中南大学 | 微生物复合菌剂及其制备方法和赤泥原位生物脱碱的方法 |
| CN116903760A (zh) * | 2023-05-25 | 2023-10-20 | 浙江大学 | 木耳多糖及其制备方法和抑制肥胖的用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2000044468A (ja) * | 1998-07-29 | 2000-02-15 | Kikkoman Corp | リパーゼ阻害剤及び抗肥満剤又は高脂血症抑制剤 |
| DK1254209T3 (da) * | 2000-08-17 | 2006-07-24 | Sabinsa Corp | Sammensætning omfattende hydroxycitronsyre og garcinol til vægttab |
| AU2011352073B2 (en) * | 2010-12-30 | 2015-12-24 | Sami Labs Limited | Hepatoprotectant activity of garcinol |
| US8329743B2 (en) * | 2011-01-10 | 2012-12-11 | Sami Labs Limited | Compositions and its use in treating obesity or inducing weight loss |
| CA3092318A1 (en) * | 2012-09-20 | 2014-03-27 | Prothera, Inc. | Probiotic compositions and methods for the treatment of obesity and obesity-related conditions |
| US9872840B2 (en) * | 2013-10-03 | 2018-01-23 | Delhi Institute Of Pharmaceutical Sciences And Research | Effect of garcinol in delaying the progression of diabetic nephropathy |
| KR102356094B1 (ko) * | 2014-03-24 | 2022-01-26 | 주식회사 다이셀 | 약학 조성물 |
| CA2934156A1 (en) * | 2015-11-10 | 2017-05-10 | Muhammed Majeed | Use of forskolin in the treatment of obesity |
-
2018
- 2018-06-13 BR BR112019026824-3A patent/BR112019026824A2/pt unknown
- 2018-06-13 WO PCT/US2018/037242 patent/WO2018231923A1/en unknown
- 2018-06-13 KR KR1020197038979A patent/KR102289324B1/ko active IP Right Grant
- 2018-06-13 JP JP2019569248A patent/JP2020523373A/ja active Pending
- 2018-06-13 CA CA3066446A patent/CA3066446A1/en active Pending
- 2018-06-13 EP EP18817304.1A patent/EP3638226A4/de active Pending
- 2018-06-13 AU AU2018284354A patent/AU2018284354A1/en active Pending
- 2018-06-13 MX MX2019014841A patent/MX2019014841A/es unknown
-
2021
- 2021-08-10 JP JP2021130804A patent/JP2021185156A/ja active Pending
-
2022
- 2022-04-15 JP JP2022067326A patent/JP2022097521A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021185156A (ja) | 2021-12-09 |
| KR20200012978A (ko) | 2020-02-05 |
| WO2018231923A1 (en) | 2018-12-20 |
| BR112019026824A2 (pt) | 2020-06-30 |
| EP3638226A4 (de) | 2021-04-07 |
| KR102289324B1 (ko) | 2021-08-12 |
| JP2020523373A (ja) | 2020-08-06 |
| EP3638226A1 (de) | 2020-04-22 |
| MX2019014841A (es) | 2020-02-17 |
| JP2022097521A (ja) | 2022-06-30 |
| AU2018284354A1 (en) | 2020-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3066446A1 (en) | Anti-obesity potential of garcinol | |
| He et al. | Rhizoma Coptidis alkaloids alleviate hyperlipidemia in B6 mice by modulating gut microbiota and bile acid pathways | |
| Liu et al. | Extracellular vesicles from child gut microbiota enter into bone to preserve bone mass and strength | |
| Lee et al. | Blueberry supplementation influences the gut microbiota, inflammation, and insulin resistance in high-fat-diet–fed rats | |
| Liu et al. | Grape seed proanthocyanidin extract ameliorates inflammation and adiposity by modulating gut microbiota in high‐fat diet mice | |
| JP6954563B2 (ja) | 代謝障害を処置するための低温殺菌アッカーマンシアの使用 | |
| Wang et al. | Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis | |
| Lee et al. | Garcinol reduces obesity in high‐fat‐diet‐fed mice by modulating gut microbiota composition | |
| Tang et al. | A synbiotic consisting of Lactobacillus plantarum S58 and hull-less barley β-glucan ameliorates lipid accumulation in mice fed with a high-fat diet by activating AMPK signaling and modulating the gut microbiota | |
| Karimi et al. | Single-species versus dual-species probiotic supplementation as an emerging therapeutic strategy for obesity | |
| US20200030388A1 (en) | Compositions for modifying gut microbiota | |
| Ge et al. | Luteolin cooperated with metformin hydrochloride alleviates lipid metabolism disorders and optimizes intestinal flora compositions of high-fat diet mice | |
| US20180360776A1 (en) | Anti-obesity potential of garcinol | |
| Yan et al. | Oryzanol alleviates high fat and cholesterol diet-induced hypercholesterolemia associated with the modulation of the gut microbiota in hamsters | |
| Sun et al. | Tea polyphenols protect mice from acute ethanol-Induced liver injury by modulating the gut microbiota and short-chain fatty acids | |
| Albuquerque et al. | Saccharomyces boulardii Tht 500101 changes gut microbiota and ameliorates hyperglycaemia, dyslipidaemia, and liver inflammation in streptozotocin-diabetic mice | |
| Kou et al. | Nobiletin activates thermogenesis of brown and white adipose tissue in high‐fat diet‐fed C57BL/6 mice by shaping the gut microbiota | |
| Sheykhsaran et al. | Gut microbiota and obesity: an overview of microbiota to microbial-based therapies | |
| Lu et al. | Prevention of high-fat diet-induced hypercholesterolemia by Lactobacillus reuteri Fn041 through promoting cholesterol and bile salt excretion and intestinal mucosal barrier functions | |
| Keshavarz Azizi Raftar et al. | The anti-fibrotic effects of heat-killed Akkermansia muciniphila MucT on liver fibrosis markers and activation of hepatic stellate cells | |
| Seo et al. | Effects of kefir lactic acid bacteria-derived postbiotic components on high fat diet-induced gut microbiota and obesity | |
| Yu et al. | Casein-fed mice showed faster recovery from DSS-induced colitis than chicken-protein-fed mice | |
| Yu et al. | Secoisolariciresinol diglucoside-derived metabolite, enterolactone, attenuates atopic dermatitis by suppressing Th2 immune response | |
| Miao et al. | Long-term use of Lacticaseibacillus paracasei N1115 from early life alleviates high-fat-diet-induced obesity and dysmetabolism in mice | |
| Zhang et al. | Taraxacum officinale-derived exosome-like nanovesicles modulate gut metabolites to prevent intermittent hypoxia-induced hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220421 |
|
| EEER | Examination request |
Effective date: 20220421 |
|
| EEER | Examination request |
Effective date: 20220421 |
|
| EEER | Examination request |
Effective date: 20220421 |
|
| EEER | Examination request |
Effective date: 20220421 |
|
| EEER | Examination request |
Effective date: 20220421 |
|
| EEER | Examination request |
Effective date: 20220421 |